Article

Microplasmin receives orphan drug protection

Dublin-The FDA has classified a new microplasmin compound for use in pediatric vitrectomy as an orphan drug.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
NIH highlights 5 key elements of cortical visual impairment (CVI)
November 23rd 2024

NIH highlights 5 key elements of cortical visual impairment (CVI)

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Cerebral visual impairment is a growing concern in pediatric vision loss
November 14th 2024

Cerebral visual impairment is a growing concern in pediatric vision loss

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

FDA grants fast track status to FELIQS’ FLQ-101 for ROP
November 6th 2024

FDA grants fast track status to FELIQS’ FLQ-101 for ROP

Cerebral visual impairment: A growing concern in pediatric vision loss
October 30th 2024

Cerebral visual impairment: A growing concern in pediatric vision loss

© 2024 MJH Life Sciences

All rights reserved.